Seed funding will be used to develop software tools to make prescribing medications simple, safe, and efficient for doctors and their patients
CHATTANOOGA, Tenn.--(BUSINESS WIRE)--EirSystems, an emerging leader in software development for prescribing and distributing prescriptions safely and efficiently, recently closed a seed funding round led by Solas BioVentures. Additional investors included several Chain Reaction Boston investors led by Ken Mooney. With this funding, EirSystems will continue to secure partnerships and grow market share in the e-prescribing market.
"EirSystems' innovation in the e-prescription market is second to none. This technology will help physicians better serve their patients' wellbeing with faster and more accurate information at hand," commented David Adair, MD, M.B.A., Co-Founder and Managing Director of Solas BioVentures. "We fully support their growth and look forward to the company's future."
"We are delighted to co-invest with Solas BioVentures in this round of financing for EirSystems," said Eliza Petrow, Managing Director at Chain Reaction Boston. "At Chain Reaction, our group of angel investors is focused on funding innovative blockchain-based solutions, including in the healthcare space, and EirSystems fits that profile nicely."
"We are incredibly grateful to work with Solas BioVentures and Chain Reaction to secure our latest funding round. We believe our partnership with Solas will allow EirSystems to make more partnerships in the healthcare industry, allowing our product to grow quickly over the next few years," stated EirSystems CEO Tyler Seaberg. "Specifically, this funding will enable us to ramp up production, expand our support teams by hiring talent from the Chattanooga area and, in 2023, release new product offerings for medication management and prescription drug claims designed to impact the prescribing space significantly."
EirSystems' proprietary P.A.G.R. (Prescription Abuse Greatly Reduced) is an advanced software platform providing physicians and pharmacists the tools they need to make the prescribing process simple, safe, and efficient for their patients. P.A.G.R. can be integrated or installed into any system and operates in one easy-to-use web interface.
About EirSystems
EirSystems Inc. was founded in 2018 by brothers Ryan and Tyler Seaberg to provide doctors with a one-stop shop for all their prescribing needs. Having been personally affected by the opioid crisis, the brothers bring unique insight and drive to solve today's problems in the prescribing market. To better understand and address these problems, Ryan and Tyler consult with several healthcare professionals and their father, David Seaberg, a 30+ year physician.
EirSystems serves customers in numerous sectors of the healthcare market, including hospice, home health, small and medium-sized clinics, and telehealth platforms. This fundraising round will be used to continue growing their team and securing new partnerships to improve P.A.G.R.'s real-time benefits functionality to identify less expensive and safer medications, and develop exciting, new features including a medication management platform. The rollout of these new features is planned for 2023. For more information, visit www.eirsystems.net
About Solas BioVentures
Solas BioVentures is a venture capital firm that invests exclusively in the life science industry, focusing on early and development-stage biotech and medtech companies advancing impactful, disruptive technologies. Headquartered in Chattanooga, Tennessee, its coverage is global. For more information, visit solasbio.com.
About Chain Reaction
Chain Reaction is a Boston-based angel investment group that infuses innovative early-stage blockchain startups with fast funding, invaluable mentorship, and unparalleled networking opportunities. Investor members are committed to accelerating the investment process, delivering strong returns and strengthening the blockchain ecosystem across the U.S. For more information, visit www.chainreactionboston.com.
Contacts
Scott Yates
OnPoint Communications
919-649-6621
scott@onpointprgroup.com